News Column

Researchers from Avicenne Teaching Hospital Report Details of New Studies and Findings in the Area of Gene Therapy (Interleukin-35 gene therapy...

September 11, 2014



Researchers from Avicenne Teaching Hospital Report Details of New Studies and Findings in the Area of Gene Therapy (Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Biotechnology are discussed in a new report. According to news reporting out of Bobigny, France, by NewsRx editors, research stated, "Interleukin (IL)-35 was initially described as an immunosuppressive cytokine specifically produced by CD4(+)FoxP3(+) regulatory T cells (Treg). Since Treg play a major role in autoimmunity control and protect from inflammation, we aimed at evaluating the role of IL-35 in collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis (RA), using a non-viral gene transfer strategy."

Our news journalists obtained a quote from the research from Avicenne Teaching Hospital, "The clinical and histological effect of IL-35 was assessed in mice with CIA receiving an injection of two distinct plasmids encoding IL-35 gene (pIGneo-mIL-35 or pORF-mIL-35) 3 and 18 days after CIA induction. Treg and Th17 were characterized by flow cytometry in the spleen and lymph nodes of treated mice. Our results showed that whatever the plasmid used, IL-35 gene transfer resulted in a statistically significant increase in clinical scores of CIA compared to results with empty plasmid. The underlying cellular mechanisms of this effect were shown to be related to an increased Th17/Treg ratio in the spleen of pORF-mIL-35 treated mice."

According to the news editors, the research concluded: "We show an unexpected but clear exacerbating effect of IL-35 gene transfer in an autoimmune and inflammatory RA model, associated with a modification of the Th17/Treg balance. Altogether, these result shows that this cytokine can promote chronic inflammation."

For more information on this research see: Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine, 2014;69(1):87-93. Cytokine can be contacted at: Academic Press Ltd- Elsevier Science Ltd, 24-28 Oval Rd, London NW1 7DX, England. (Elsevier - www.elsevier.com; Cytokine - www.elsevier.com/wps/product/cws_home/622815)

Our news journalists report that additional information may be obtained by contacting A. Thiolat, Avicenne Hosp, AP HP, Dept. of Rheumatol, F-93009 Bobigny, France. Additional authors for this research include A. Denys, M. Petit, J. Biton, D. Lemeiter, R. Herve, D. Lutomski, M.C. Boissier and N. Bessis (see also Biotechnology).

Keywords for this news article include: Bobigny, France, Europe, Bioengineering, Biotechnology, Cytokines, Gene Therapy, Inflammation, Interleukins, Joint Diseases, Musculoskeletal Diseases, Rheumatoid Arthritis

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters